2024 annual financial data
Foghorn Therapeutics 2024 Revenue growth
Direct answer
Revenue growth was -33.83%.
Operating income was -102,683,000 USD and net income was -86,620,000 USD.
Operating cash flow was -100,406,000 USD.
Get free Foghorn Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 22,602,000 USD
- Operating income
- -102,683,000 USD
- Net income
- -86,620,000 USD
- Operating cash flow
- -100,406,000 USD